Navigation Links
Yongye Biotechnology Announces Record Third Quarter Results

BEIJING, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals in the People's Republic of China, today announced its financial results for the quarter ended September 30, 2008.

Third Quarter 2008 Highlights

-- Revenue was $18.2 million, an increase of 593.4% from the third quarter

of 2007

-- Gross profit was $8.9 million, a 456.6% increase from the third quarter

of 2007, with a gross margin of 49.0%

-- Net income was $4.5 million, an increase of 283.5% from the third

quarter of 2007, or $0.22 per diluted share

-- Closed a private placement with gross proceeds of $9.35 million in

September 2008

-- Opened a new production facility in Hohhot that increased production

capacity from 2,000 to 10,000 metric tons per year

Third Quarter 2008 Results

"Our third quarter sales exceeded our second quarter sales even though the second quarter of each year is typically our strongest quarter. Revenue increased almost six fold in the third quarter of 2008 from the third quarter of 2007, and net income more than doubled over the same period," said Mr. Zishen Wu, Chief Executive Officer of Yongye. "Rapid growth resulted from strong demand for our plant nutrient product which we created through the recent expansion of our distribution network which sells to our branded stores. We produce some of the purest and most bioactive fulvic acid based plant and animal nutrients in China, and our recent success supports our plans to increase our presence in the provinces in which we already are located."

Revenue was $18.2 million in the third quarter of 2008, an increase of 593.4% from $2.6 million in the third quarter of 2007. This significant revenue increase was due mainly to the rapid expansion of the Company's sales network of stores. An additional 575 branded stores were added to the network in the first half of 2008, bringing the total number of stores through which the Company distributed its products in the third quarter to 775. The expanded sales network resulted in a total volume of 182,009 units sold of both plant and animal products in the third quarter of 2008, a 427.6% increase from 34,496 units sold in the third quarter of 2007. The Company's plant nutrient product accounted for 99.9% of sales revenue in the third quarter of 2008.

Gross profit was $8.9 million in the third quarter of 2008, a 456.6% increase from $1.6 million in the third quarter of 2007. Gross margin was 49.0% compared to 61.1% in the third quarter of 2007. Margin declined mostly because of discounts being given to key distributors and the cost of production being higher in 2008 compared to 2007.

Selling, General and Administrative expenses were $3.9 million in the third quarter of 2008, compared to $355,784 in the third quarter of 2007. These expenses as a percentage of sales increased because of expanded advertising, adding new management personnel, and freight costs of $3,408,813 compared to $140,205 in the third quarter of 2007, an increase of $3,268,608, or 2,331%. Freight costs increased dramatically because the Company distributed products to ten provinces in the third quarter of 2008 compared to four provinces in the third quarter of 2007. The predecessor company that existed in 2007 that became Yongye had a cost structure that was similar to Yongye's current cost structure, but on a much smaller scale.

Income from Operations was $5.0 million in the third quarter of 2008, with operating margin of 27.6%, compared to $1.2 million during the third quarter of 2007, with operating margin 47.5%.

Net income grew 283.5% to $4.5 million in the third quarter of 2008, or $0.22 per diluted share, compared to net income of $1.2 million, or $0.10 per diluted share, in the third quarter of 2007.

The diluted weighted average number of shares outstanding increased from 11,444,775 in the third quarter of 2007 to 20,103,760 in the quarter ended September 30, 2008 because additional shares were issued in private placements in April and September 2008.

Nine Months 2008 Results

Net revenue was $45.2 million in the nine months ended September 30, 2008, up 320.3% from $10.8 million for the nine months ended September 30, 2007. Gross profit was $23.5 million with a gross margin of 52.0%, compared to $5.4 million with a gross margin of 50.1% for the nine months ended September 30, 2007. Operating income was $14.8 million with an operating margin of 32.7%, compared to $4.8 million with an operating margin of 44.7% in the nine months ended September 30, 2007. Net income was $12.2 million, or $0.75 per diluted share, compared to $4.5 million, or $0.40 per diluted share, for the nine months ended September 30, 2007.

Financial Condition

On September 30, 2008, cash totaled $6.8 million, compared to $376,002 as of December 31, 2007. The cash balance increased because of increased cash sales, collections of the previous quarter accounts receivable and the private placement that took place in September 2008.

Accounts receivable was $20.7 million as of September 30, 2008, compared to $1.6 million as of December 31, 2007. This large accounts receivable is due in part to the high level of sales throughout the third quarter. Additionally, it is customary in China's agriculture industry to extend credit terms which allow distributors to pay over a longer period of time than what may be usual in other industries. Consequently, the collection cycle for accounts receivable tends to take longer than in other industries. The Company has every reason to believe that its accounts receivable will be paid under the terms extended to its customers through the end of 2008. As of September 30, 2008, Yongye did not have any accounts receivable that were uncollected beyond 180 days.

As of September 30, 2008, the Company had total assets of $35.6 million, compared to $23.1 million as of December 31, 2007. Working capital was $28.4 million, total current liabilities were $3.7 million and the Company had $204,962 in long term liabilities. Stockholders' equity totaled $30.5 million as of September 30, 2008, compared to $12.9 million at the end of 2007. Illustrating differences between Yongye Nongfeng and the predecessor company it spun off from in 2008, changes in working capital over the nine month period ended September 30, 2008 were primarily due to a decrease in inventory of $7,791,256, reflecting Yongye Nongfeng's current business model of purchasing only finished goods as inventory, an increase in cash of $6,471,556 due mostly to two financings, increased sales capability, and a large accounts receivable increase of $19,048,258 because of greater sales volume.

Key Events and Changes

In September, the Company closed a private placement financing through which the Company issued 6,073,006 shares of its common stock for gross proceeds of approximately $9.4 million. The proceeds from this placement are being used to pay for the Company's recently opened production facility and for organizational restructuring.

As described in its September Financing Disclosure Schedule, Yongye acquired its predecessor company's manufacturing equipment and will acquire remaining land use rights, buildings, equipment and permits which currently belong to its predecessor and outsourced manufacturing partner Inner Mongolia Yongye once the predecessor and manufacturing partner are ready to transfer their fertilizer manufacturing license to Yongye Nongfeng. This will enable Yongye Nongfeng to centralize and better manage the Company's product research and development, manufacturing, marketing and distribution. The Company hopes to become a more tightly integrated business with greater control over product quality and intellectual property.

In October, the Company opened a new production facility in Hohhot, Inner Mongolia. This new facility added 8,000 metric tons of production capacity per year. Yongye expects the new facility to reach an annual average utilization rate of 60% for 2009. The new facility brings the Company's total production capacity to 10,000 metric tons per year.

Business Outlook

"China's government recently announced that land reform will take place through which farmers will be allowed to sell or trade their land rights. We expect this reform to lead to larger and better managed farms, which should increase demand for our products," said Mr. Wu. "China's government also recently announced a major economic stimulus program that includes rural development. Details of what will take place are not yet available, but should have the effect of raising rural incomes and increasing demand for higher quality food products."

We look forward to utilizing our new increased production capacity to meet growing demand for our products. We plan to continue growing by deepening the penetration of our distribution and sales network, and eventually broadening our geographic market coverage. We also plan to increase our ability to provide technical assistance to our customers and help them achieve the best possible results through use of our products," stated Mr. Wu. "As part of the private placement financing that took place in April 2008, we entered into a 'make good' agreement that set a target of a minimum of $10.3 million in net income for fiscal year 2008. I am pleased to report that we have exceeded our make good target as of the third quarter of 2008. We expect to achieve 2009 make good targets of $44 million in revenue and $15.2 million in net income."

Conference Call

The Company will host a conference call at 08:00 a.m. Eastern time on Thursday, November 13, 2008 to discuss its third quarter 2008 results.

To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: +1- 888-482-0024. International callers should dial +1-617-801-9702. The conference pass code is 544 101 83.

For those who are unable to participate in the conference call at the time of the call, a replay will be available for fourteen days after the call is held. To access the replay, please dial +1-888-286-8010. International callers should dial +1-617-801-6888. The replay pass code is 746 062 47.

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products which increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Safe Harbor Statement

This press release contains certain statements that may include "forward looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website ( ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

-- Financial Tables Follow --



Yongye The Yongye The

Biotechnology predecessor Biotechnology predecessor

International, Inner International, Inner

Inc. and Mongolia Inc. and Mongolia

Subsidiaries Yongye Subsidiaries Yongye

For Three For Three For Nine For Nine

Months Ended Months Ended Months Ended Months Ended

September 30, September 30, September 30, September

2008 2007 2008 30, 2007

(Unaudited) (Unaudited) (Unaudited) (Unaudited)

Sales $18,202,940 $2,625,137 $45,189,579 $10,752,855

Cost 9,278,944 1,021,719 21,697,964 5,368,480

Gross Profit 8,923,996 1,603,418 23,491,615 5,384,375

Operating Expenses 3,440,036 159,398 7,437,513 230,591

General and


Expenses 453,683 196,386 1,265,808 351,372

Income from

Operations 5,030,277 1,247,634 14,788,294 4,802,412

Other Income


Interest Income 65,785 -- 66,563 1,291

Other Income (340,087) (81,827) (726,927) (279,468)

Total Other Income

(Expenses) (274,302) (81,827) (660,364) (278,177)

Income (Loss)

Before Provision

for Income Taxes

and Minority

Interest 4,755,975 1,165,807 14,127,930 4,524,235

Provision for

Income Taxes 227,537 -- 822,302 --

Net Income (Loss)

before Minority

Interest 4,528,438 1,165,807 13,305,628 4,524,235

Provision for

Minority Interest 57,421 -- 1,092,426 --

Net Income 4,471,017 1,165,807 12,213,202 4,524,235

Foreign Currency


Adjustment 5,199 170,033 419,970 344,228


Income $4,476,216 $1,335,840 $12,633,172 $4,868,463

Net Income Per


Basic $0.24 $0.10 $0.78 $0.40

Diluted $0.22 $0.10 $0.75 $0.40

Weighted Average


Basic 18,637,948 11,444,775 15,654,417 11,444,775

Diluted 20,103,760 11,444,775 16,335,237 11,444,775



Yongye Biotechnology The predecessor

International, Inc. Inner Mongolia

and Subsidiaries Yongye

September 30, 2008 December 31, 2007



Cash and Cash Equivalents $6,847,558 $376,002

Accounts Receivable 20,678,867 1,630,609

Inventories 2,060,532 9,851,788

Advance Payments 273,722 --

Due from Affiliates 954,431 978,384

Other Receivables 1,247,929 27,038

Total Current Assets 32,063,039 12,863,821

PROPERTY AND EQUIPMENT, NET 3,386,463 2,486,487

INTANGIBLE ASSETS, NET 114,817 3,665,584


TOTAL ASSETS $35,564,319 $23,131,656


Accounts Payable and Accrued

Expenses 1,503,005 1,271,852

Short-term Bank Loan -- 5,484,000

Due to Shareholders -- 2,507,371

Due to Related Parties 1,646,282

Tax Payables 414,997 893,892

Other Payables 85,986 50,916

Total Current Liabilities 3,650,270 10,208,031

LONG-TERM LIABILITY 204,962 12,153

Minority Interest 1,192,426 --


Capital Stock: 26,760,258 shares

authorized and issued par value

$.001 as of September 30, 2008 26,760 --

Capital Contribution -- 7,260,000

Additional Paid-in Capital 17,887,832 --

Retained Earnings 10,918,386 4,024,111

Statutory Reserve 1,263,713 480,629

Accumulated other

Comprehensive Income 419,970 1,146,732

Total Stockholders' Equity $30,516,661 $12,911,472


EQUITY $35,564,319 $23,131,656



Yongye The

Biotechnology predecessor

International, Inc. Inner Mongolia

and Subsidiaries Yongye

For Nine Months For Nine

Ended June 30, Months Ended

2008 June 30, 2007

(Unaudited) (Unaudited)


Net Income $12,213,202 $4,524,235

Adjustments to Reconcile Net

Income to Net Cash Used in

Operating Activities

Depreciation and Amortization 115,541 160,978

Loss on Disposal of Fixed Assets 146,714

Provision for Minority Interest 1,092,426 --

Changes in Assets and Liabilities:

Accounts Receivable, net (20,628,654) (1,116,746)

Inventories (2,046,871) (5,211,663)

Other Receivables, net (1,247,729) (518,729)

Advances to Suppliers (273,630) 85,904

Prepaid Expense -- (4,374)

Accounts Payable and

Accrued Expenses 1,484,826 (77,148)

Deposit Received 120

Taxes Payable 414,009 58,074

Due from Related Parties (954,735)

Due to Related Parties 1,626,548 (225,171)

Other Payables 85,783 (1,391,508)

Total Adjustments (20,332,366) (8,093,669)

Net Cash Used in Operating

Activities (8,119,164) (3,569,434)



Acquisition of Property and

Equipment (3,493,192) (96,165)

Additions to Intangible

Assets (122,899)

Net Cash Used in Investing

Activities (3,616,091) (96,165)


Proceeds from Bank Loans 205,028 4,251,841

Proceeds from Share Capital 19,135,151

Proceeds from Shareholder Loans -- 831,157

Repayment of Long-term Loans -- (6,500)

Payment for Stock Issuance Costs (1,146,159) --

Net Cash From Financing Activities 18,194,020 5,076,498


TRANSLATION ON CASH 380,656 (32,791)


EQUIVALENTS 6,839,421 1,443,690


BEGINNING 8,137 89,023


ENDING $6,847,558 $1,532,713

Supplemental cash flow information:

Cash paid for income taxes 424,725 --

Cash paid for interest expense

payment -- 138,955

For more information, please contact:

Yongye Biotechnology International, Inc.

Mr. Larry Gilmore-VP of Corporate Strategy

Phone: +1-818-390-1272


CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Phone: +1-646-213-1915 (New York)



SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
2. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
3. Yongye Biotechnology International Raises $9.4 Million in Private Placement
4. Yongye Biotechnology International Announces Second Quarter Results
5. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
6. Yongye Biotechnology International Retains CCG Investor Relations
7. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
8. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
9. World Market for Biotechnology Reagents to Reach $32.5 Billion by 2012, According to New Report by Global Industry Analysts, Inc.
10. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
11. InNexus Biotechnology Receives Patent Grants in Europe
Post Your Comments:
(Date:10/12/2017)... FL (PRWEB) , ... October ... ... (RPS®) today announces publication of a United States multicenter, prospective clinical study ... use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, ... in analytical testing are being attributed to new regulatory requirements for all new ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):